Experimental “vascular” headache in humans may be used in characterizing new migraine drugs. The effects of sumatriptan on nitroglycerin-(NTG)-induced headache and arterial responses were therefore studied. Following a double-blind randomized crossover design, 10 healthy volunteers received sumatriptan 6 mg s.c. or placebo succeeded by 20 min NTG (0.12 mg/kg/min) infusion. Headache was rated on a 10 points scale. Temporal and radial artery diameters and velocity in the middle cerebral artery (MCA) were measured with ultrasound. Sumatriptan reduced the NTG-induced headache, median score 1.5 versus 4 after placebo (p<0.01) and decreased temporal and radial artery diameters 75±3 and 86±3% of baseline respectively (p<0.05), Blood velocity in the MCA was unaffected. The NTG model may prove to be a valuable tool in the development of future migraine drugs. The results suggest that NTG headache in non-migraineurs may share mechanisms with migraine headache.
IversenHKOlesenJTfelt-HansenP.Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics.
Pain1989;
38:
17–24
2.
IversenHKNielsenTHGarreKTfelt-HansenPOlesenJ.Dose-dependent headache response and dilatation of extremity and extracranial arteries after three doses of 5-isosorbide-monomitrate.
Eur J Clin Pharmacol1992;
42:
31–35
3.
IversenHKNielsenTHTfelt-HansenPOlesenJ.Lack of tolerance of headache and radial artery diameter curing a 7 hour intravenous infusion of nitroglycerin.
Eur J Clin Pharmacol1993;
44:
47–50
4.
IversenHKHolmSFribergL.Intracranial hemodynamics during intravenous nitroglycerin infusion.
Cephalalgia1989;
9Suppl 10:
84–5
5.
FribergLOlesenJIversenHKSperlingB.Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan.
Lancet1991;
338:
13–17
6.
IversenHKNielsenTHOlesenJTfelt-HansenP.Arterial responses during migraine headache.
Lancet1990;
336:
37–9
7.
ThomsenLLIversenHKOlesenJ.Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura.
Cephalalgia1995;
15:
109–16
8.
ZwetslootCPCaekebekeJFVFerrariMD.Lack of asymmetry of middle cerebral artery blood velocity in unilateral migraine.
Stroke1993:
24:
1335-8
9.
OlesenJIversenHKThomsenLL.Nitric oxide supersensitivity. A possible molecular mechanism of migraine pain.
Neuroreport1993;
4:
1027–30
10.
ThomsenLLIversenHKBrinckTAOlesenJ.Arterial supersensitivity to nitric oxide in migraine sufferers.
Cephalalgia1993;
13:
395–9
11.
IversenHK.N-acetylcysteine potentiates nitroglycerin induced headache and dilatation of cranial but not extremity arteries.
Clin Pharmacol Ther1992;
52:
125–33
12.
DechantKLClissoldSP.Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache.
Drugs1992;
45:
776–98
13.
NielsenTHIversenHKTfelt-HansenPOlesenJ.Small arteries can be accurately studied in-vivo, using high frequency ultrasound.
Ultrasound Med Biol1993;
19:
717–25
14.
NielsenTHIversenHKTfelt-HansenP.Determination of the luminal diameter of the radial artery in man by high frequency ultrasound. A methodological study.
Ultrasound Med Biol1990;
8:
787–91
15.
ThomsenLLIversenHK.Experimental and biological variations in three dimensional transcranial Doppler measurements.
J Appl Physiol1993;
75:
2805–10
16.
MatthewsJNSAltmanDGCambellMJRoystonP.Analysis of serial measurements in medical research.
Br Med J1990;
300:
230–5
17.
HollanderMWolfeDA.Nonparametric statistical methods.
New York:
Wiley,
1973
18.
FeniukWHumphreyPPAPerrenMJ.The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs.
Br J Pharmacol1989:
96:
83–90
19.
CaekebekeJFVFerrariMDZwetslootCPJansenJSaxenaPR.Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks.
Neurology1992:
42:
1522-6
20.
JansenJEdvinssonLOlesenJ5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences.
Acta Physiol Scand1993:
147:
141-50
21.
BuzziMGMoskowitzMA.Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine.
Cephalalgia1991;
11:
165–8
22.
MacLennanSJMartinGR.Effect of thromboxane A2-mimetic U46619 on 5HT1-LIKE and 5HT2 receptors3/4mediated contraction of the rabbit isolated femoral artery.
Br J Pharmacol1992;
107:
418–21
23.
Den BoerMOVillalónCMHeiligersJPCHumphreyPPASaxenaPR.Role of 5HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.
Br J Pharmacol1991;
102:
323–30
24.
BrennumJKjeldsenMOlesenJ.The 5HT1-LIKE agonist sumatriptan has a significant effect in chronic tension-type headache.
Cephalalgia1992;
12:
375–79
25.
SicuteriFBeneEDPoggioniMBonnazziA.Unmasking latent dysnociception in healthy subjects.
Headache1987;
27:
180–5
ShekharYCAnandISSarmaRFerrariRWahiPLPoole-WilsonPA.Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure.
Am J Cardiol1991;
67:
732–6
28.
OlesenJPaulsonOB.The effect of intra-arterial papaverine on the regional cerebral blood flow in patients with stroke or intracranial tumors.
Stroke1971;
2:
148–59
